<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659499</url>
  </required_header>
  <id_info>
    <org_study_id>MA-BC-II-007</org_study_id>
    <nct_id>NCT04659499</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Single-arm, Phase II Clinical Trial of Nab-paclitaxel in Combination With Pyrotinib in Adjuvant Therapy for Lymph Node-negative and Small Tumor HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to&#xD;
      evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients&#xD;
      with lymph node-negative and tumor size ≤3 cm, HER2 positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year-DFS</measure>
    <time_frame>From the start of treatment to 3 years</time_frame>
    <description>3-years-disease free survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>from the first drug administration to within 28 days for the last pyrotinib dose</time_frame>
    <description>Adverse Events and Serious Adverse Events are described in terms of CTC AE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">261</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel in combination with pyrotinib treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib 240mg daily for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel in combination with pyrotinib</intervention_name>
    <description>Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year</description>
    <arm_group_label>Nab-paclitaxel in combination with pyrotinib treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrollment subjects must have a pathological diagnosis of HER2-positive primary&#xD;
             invasive breast cancer with an immunohistochemistry (IHC) score of 3 +, or 2 + and&#xD;
             HER2 gene amplification by in situ hybridization (ISH) (ratio of HER2/CEP17 ≥ 2.0).&#xD;
&#xD;
          -  The invasive tumor had to measure no more than 3cm and with histologically confirmed&#xD;
             lymph node-negative or one lymph node micrometastasis (T ≤ 3 cm, N0/N1mi, M0).&#xD;
&#xD;
          -  Tumor should has known ER/PR hormone receptor status.&#xD;
&#xD;
          -  All patients must be women above18 years old with Eastern Cooperative Oncology Group&#xD;
             score 0 to 1.&#xD;
&#xD;
          -  Adequate hematopoietic function and organ function as defined as follows: neutrophil&#xD;
             count ≥ 1.5 x 109/L; Platelet count ≥ 90 × 109/L; Hemoglobin ≥ 90 g/L; total bilirubin&#xD;
             ≤ 1.5 × ULN; alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3 × ULN;&#xD;
             serum creatinine Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault&#xD;
             formula).&#xD;
&#xD;
          -  left ventricular ejection fraction (LVEF) ≥ 50% and Electrocardiogram&#xD;
             Fridericia-corrected QT interval (QTcF) ≤ 480 ms.&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or radiologic evidence of local or regional recurrence of disease or&#xD;
             metastatic disease prior to or at the time of study entry.&#xD;
&#xD;
          -  Previous treatment with chemotherapeutic drugs, or tyrosine kinase inhibitors&#xD;
             targeting HER2 (lapatinib, neratinib or pyrotinib, etc.).&#xD;
&#xD;
          -  Other malignancies within the past 5 years, excluding cured cervical carcinoma in&#xD;
             situ, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.&#xD;
&#xD;
          -  Inability to swallow, chronic diarrhea, or intestinal obstruction.&#xD;
&#xD;
          -  Known to be allergic to the drug components.&#xD;
&#xD;
          -  Have a history of immunodeficiency, including HIV positive, HCV positive, active viral&#xD;
             hepatitis B or other immunodeficiency diseases.&#xD;
&#xD;
          -  Have a history of organ transplantation.&#xD;
&#xD;
          -  Pregnant, lactating female patients, or female patients who are unwilling to take&#xD;
             effective contraceptive.&#xD;
&#xD;
          -  Any heart disease, including: (1) arrhythmia; (2) myocardial infarction; (3) heart&#xD;
             failure.&#xD;
&#xD;
          -  Any other concomitant diseases assessed by investigator as unsuitable for study.&#xD;
&#xD;
          -  Previous history of definite neurological or psychiatric disorders.&#xD;
&#xD;
          -  Concomitant use of CYP3A4 inhibitors or inducers or drugs that prolong the QT&#xD;
             interval.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiang Sun, MD</last_name>
    <phone>+861069152700</phone>
    <email>sunqiangpumc@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Changjun Wang, MD</last_name>
    <phone>+861069158721</phone>
    <email>wangchangjun@pumch.cn</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

